Article Text
PDF
Abstract
Introduction/Background The recommendation of adjuvant treatment following radical hysterectomy in early stage cervical cancer is usually tailored according to International Federation of Gynecology and Obstetrics (FIGO) stage and risk factors
Methodology - The aim of the study was to assess the outcome of early cervical cancer patients who underwent radical hysterectomy followed by adjuvant treatment.
Design- Retrospective cohort study
Methods- The medical records of 131 patients who underwent radical hysterectomy for early stage cervical cancer FIGO 2018 Stage I to IIA1 were assessed for clinical and histopathologic features. The patients were grouped into no adjuvant treatment, adjuvant radiation or adjuvant chemoradiation with weekly cisplatin. The adjuvant treatment received was based on the presence of high risk factors like nodal, parametrial or margin involvement and intermediate risk factors like lymphovascular involvement, deep stromal involvement or size >4 cm.
Results 40.5% of the patients received no adjuvant treatment. 41.2% patients received adjuvant radiation, 18.3% patients received adjuvant concurrent chemoradiation. The overall survival in all three groups was 100%. The disease free survival in no adjuvant treatment group was 92%, in adjuvant radiation group was 96.2% and adjuvant chemoradiation group was 100%. Recurrence was noted in 5 patients who had no adjuvant treatment, 4 who had adjuvant radiation and one patient who had adjuvant concurrent chemoradiation .
Conclusion Adjuvant concurrent chemoradiation should be considered in early stage cervical cancers following radical hysterectomy with high risk features as it has better survival outcome.
Disclosures The authors have no conflict of interest